Differential Diagnosis for Elevated LFTs or MASLD
When evaluating elevated liver function tests or suspected MASLD, you must systematically exclude alcohol-related liver disease (ALD), viral hepatitis (B, C, A, E), autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, drug-induced liver injury, hereditary hemochromatosis, and Wilson disease before confirming MASLD. 1
Algorithmic Approach to Differential Diagnosis
Step 1: Define the Pattern and Exclude Immediate Referral Criteria
First, identify if unexplained clinical jaundice or suspicion of hepatic/biliary malignancy exists—these require immediate referral 1. For all others, proceed with systematic evaluation.
Step 2: Alcohol Intake Assessment
This is the critical first branch point in the diagnostic algorithm 2:
- Women: >20 g/day (>2 standard drinks) excludes pure MASLD
- Men: >30 g/day (>3 standard drinks) excludes pure MASLD
- 50-60 g/day threshold: Above this defines ALD; between 20-50 g/day (women) or 30-60 g/day (men) defines MetALD (combined metabolic and alcohol-related disease) 2
Clinical pearl: The AST/ALT ratio >1.5 appears in 62% of AFLD versus only 28% of MASLD, while MASLD typically shows higher ALT elevations (mean 70 U/L vs 45 U/L in AFLD) 3. However, this pattern alone is insufficient for diagnosis and requires the alcohol history to interpret correctly.
Step 3: Core Aetiology Screen (Mandatory)
The UK BALLETS-informed core panel must include 1:
- Viral hepatitis: HBsAg, anti-HCV antibody (then HCV RNA if positive), consider HAV and HEV IgM if ALT >1000 U/L
- Autoimmune: Anti-mitochondrial antibody (for PBC), anti-smooth muscle antibody, anti-nuclear antibody, IgG levels (for autoimmune hepatitis)
- Metabolic: Ferritin and transferrin saturation (hemochromatosis), ceruloplasmin if age <40 years (Wilson disease)
- Cardiometabolic markers: Fasting glucose/HbA1c, lipid panel, BMI documentation
Step 4: Pattern-Specific Considerations
For cholestatic patterns (elevated ALP, GGT):
- Consider PSC if personal/family history of autoimmune disease or inflammatory bowel disease exists—no serological markers exist, so MRI may be required upfront 1
- PBC suggested by positive anti-mitochondrial antibody with cholestatic enzymes 1
For marked transaminase elevations (ALT >1000 U/L):
- Expand viral panel to include HAV, HEV, CMV 1
- Consider acute drug-induced liver injury
Step 5: Extended Panel (Reserved for Unclear Cases)
Only perform when core panel is unrevealing 1:
- Alpha-1 antitrypsin phenotype
- Tissue transglutaminase antibodies (celiac disease)
- Thyroid function tests
- Muscle enzymes if rhabdomyolysis suspected
Step 6: Drug and Toxin History
Obtain detailed medication history including 1:
- Prescribed medications (corticosteroids, tamoxifen, methotrexate, amiodarone) 4
- Over-the-counter medications
- Herbal supplements
- Illicit drug use (including injecting drug use for viral hepatitis risk)
Step 7: Confirm MASLD Diagnosis
- Hepatic steatosis (imaging or biopsy)
- At least one cardiometabolic criterion: abdominal obesity, prediabetes/T2D, hypertension, elevated triglycerides, low HDL
- Alcohol below thresholds (as defined above)
- Exclusion of other causes from steps 2-6
Common Pitfalls to Avoid
Do not simply repeat abnormal LFTs without investigation—84% remain abnormal at 1 month, and 75% at 2 years 1. The first abnormality should trigger etiological investigation unless there is high clinical suspicion of a transient cause.
Do not assume normal LFTs exclude liver disease—even normalized tests do not necessarily imply absence or resolution of disease, particularly in established fibrosis 1.
In children, maintain a low threshold for pediatric referral, as adult causes (MASLD, ALD, viral hepatitis) are less common and the differential is broader 1.
Occupational and travel history matter—ask about tick bites, occupational exposures, and travel to hepatitis-endemic regions 1.